Glenmark Pharmaceuticals on Wednesday started Phase-IIb human trials of its 'Revamilast' molecule, which is being developed for treatment of inflammatory disorders like asthma and rheumatoid arthritis.
Glenmark starts Phase-IIb human trials of Revamilast molecule